Lisa Goeschl,Teresa Preglej,Nicole Boucheron,Victoria Saferding,Lena Mueller,Alexander Platzer,Kiyoshi Hirahara,Han-Yu Shih,Johan Backlund,Patrick Matthias,Birgit Niederreiter,Anastasiya Hladik,Maximilian Kugler,Guido A. Gualdoni,Clemens Scheinecker,Sylvia Knapp,Christian Seiser,Rikard Holmdahl,Katharina Tillmann,Roberto Plasenzotti,Bruno Podesser,Daniel Aletaha,Josef S. Smolen,Thomas Karonitsch,Guenter Steiner,Wilfried Ellmeier,Michael Bonelli

Abstract:Rheumatoid Arthritis (RA) represents a chronic T cell-mediated inflammatory autoimmune disease. Studies have shown that epigenetic mechanisms contribute to the pathogenesis of RA. Histone deacetylases (HDACs) represent one important group of epigenetic regulators. However, the role of individual HDAC members for the pathogenesis of arthritis is still unknown. In this study we demonstrate that mice with a T cell-specific deletion of HDAC1 (HDAC1-cKO) are resistant to the development of Collagen-induced arthritis (CIA), whereas the antibody response to collagen type II was undisturbed, indicating an unaltered T cell-mediated B cell activation. The inflammatory cytokines IL-17 and IL-6 were significantly decreased in sera of HDAC1-cKO mice. IL-6 treated HDAC1-deficient CD4+ T cells showed an impaired upregulation of CCR6. Selective inhibition of class I HDACs with the HDAC inhibitor MS-275 under Th17-skewing conditions inhibited the upregulation of chemokine receptor 6 (CCR6) in mouse and human CD4+ T cells. Accordingly, analysis of human RNA-sequencing (RNA-seq) data and histological analysis of synovial tissue samples from human RA patients revealed the existence of CD4+CCR6+ cells with enhanced HDAC1 expression. Our data indicate a key role for HDAC1 for the pathogenesis of CIA and suggest that HDAC1 and other class I HDACs might be promising targets of selective HDAC inhibitors (HDACi) for the treatment of RA.

Histone Deacetylase 1 (HDAC1): A Key Player of T Cell-Mediated Arthritis.